T1 at 1.5T and 3T compared with conventional T2∗at 1.5T for cardiac siderosis

Journal of Cardiovascular Magnetic Resonance

Volumn 17, Issue 1, 2015, Pages

  Alam, Mohammed H ^a,b   Auger, Dominique ^a,b   Smith, Gillian C ^a,b   He, Taigang ^c   Vassiliou, Vassilis ^a,b   Baksi, A John ^a,b   Wage, Rick ^a   Drivas, Peter ^a   Feng, Yanqiu ^d   Firmin, David N ^a,b   Pennell, Dudley J ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

3 Tesla; Cardiac siderosis; Cardiovascular magnetic resonance; MOLLI; T1 mapping; T2

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; HEART HEMOSIDEROSIS; HEMOCHROMATOSIS; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; INTERMETHOD COMPARISON; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; REPRODUCIBILITY; SICKLE CELL ANEMIA; THALASSEMIA MAJOR; CARDIAC MUSCLE; CARDIOMYOPATHIES; CASE CONTROL STUDY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; SIDEROSIS; YOUNG ADULT;

BIOLOGICAL MARKER; IRON;

ADULT; BIOMARKERS; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SIDEROSIS; YOUNG ADULT;

EID: 84947937920     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/s12968-015-0207-0     Document Type: Article

References (47)

1. Gao X, Qian M, Campian JL, Marshall J, Zhou Z, Roberts AM, et al. Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radic Biol Med. 2010;49:401-7.
2. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002;32:833-40.
3. Porter JB, Garbowski M. The pathophysiology of transfusional iron overload. Hematol Oncol Clin North Am. 2014;28:683-701.
4. Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson. 2011;13:45.
5. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2∗magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-8.
6. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, et al. On T2∗magnetic resonance and cardiac iron. Circulation. 2011;123:1519-28.
7. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9.
8. Baksi AJ, Pennell DJ. T2∗imaging of the heart: Methods, applications, and outcomes. Top Magn Reson Imaging. 2014;23:13-20.
9. House MJ, Fleming AJ, de Jonge MD, Paterson D, Howard DL, Carpenter JP, et al. Mapping iron in human heart tissue with synchrotron x-ray fluorescence microscopy and cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16:80.
10. He T, Kirk P, Firmin DN, Lam WM, Chu WC, Au WY, et al. Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. J Cardiovasc Magn Reson. 2008;10:11.
11. Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam WW, et al. International reproducibility of single breathhold T2∗MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32:315-9.
12. Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128:281-308.
13. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2∗cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
14. Meloni A, Positano V, Keilberg P, De Marchi D, Pepe P, Zuccarelli A, et al. Feasibility, reproducibility, and reliability for the T2∗iron evaluation at 3T in comparison with 1.5T. Magn Reson Med. 2012;68:543-51.
15. Guo H, Au WY, Cheung JS, Kim D, Jensen JH, Khong PL, et al. Myocardial T2 quantitation in patients with iron overload at 3 Tesla. J Magn Reson Imaging. 2009;30:394-400.
16. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99:932-7.
17. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392-8.
18. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6:488-97.
19. Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206-16.
20. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014;35:657-64.
21. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570-9.
22. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, et al. Cardiac iron determines cardiac T2∗, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535-43.
23. Feng Y, He T, Carpenter JP, Jabbour A, Alam MH, Gatehouse PD, et al. In vivo comparison of myocardial T1 with T2 and T2∗in thalassaemia major. J Magn Reson Imaging. 2013;38:588-93.
24. He T, Gatehouse PD, Kirk P, Mohiaddin RH, Pennell DJ, Firmin DN. Myocardial T2∗measurement in iron-overloaded thalassemia: An ex vivo study to investigate optimal methods of quantification. Magn Reson Med. 2008;60:350-6.
25. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52:141-6.
26. Messroghli DR, Rudolph A, Abdel-Aty H, Wassmuth R, Kühne T, Dietz R, et al. An open-source software tool for the generation of relaxation time maps in magnetic resonance imaging. BMC Med Imaging. 2010;10:16.
27. Kellman P, Hansen MS. T1-mapping in the heart: accuracy and precision. J Cardiovasc Magn Reson. 2014;16:2.
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-10.
29. Sado DM, Maestrini V, Piechnik SK, Banypersad SM, White SK, Flett AS, et al. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging. 2015;41:1505-11.
30. Abbruzzese G, Cossu G, Balocco M, Marchese R, Murgia D, Melis M, et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica. 2011;96:1708-11.
31. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-44.
32. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876-84.
33. Kellman P, Xue H, Spottiswoode BS, Sandino CM, Hansen MS, Abdel-Gadir A, et al. Free-breathing T2∗mapping using respiratory motion corrected averaging. J Cardiovasc Magn Reson. 2015;17:3.
34. Collins W, Taylor WH. Determination of iron in cardiac and liver tissues by plasma emission spectroscopy. Ann Clin Biochem. 1987;24:483-7.
35. Storey P, Thompson AA, Carqueville CL, Wood JC, de Freitas RA, Rigsby CK. R2∗imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging. 2007;25:540-7.
36. Roujol S, Weingärtner S, Foppa M, Chow K, Kawaji K, Ngo LH, et al. Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology. 2014;272:683-9.
37. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.
38. Dabir D, Child N, Kalra A, Rogers T, Gebker R, Jabbour A, et al. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2014;16:69.
39. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ, Thalassemia International Federation Heart T2∗Investigators. Multi-center validation of the transferability of the magnetic resonance T2∗technique for the quantification of tissue iron. Haematologica. 2006;91:1388-91.
40. Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, Wonke B, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2∗measurements of tissue iron in thalassemia. J Magn Reson Imaging. 2003;18:616-20.
41. Pepe A, Positano V, Capra M, Maggio A, Pinto CL, Spasiano A, et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart. 2009;95:1688-93.
42. Kirk P, Carpenter JP, Tanner MA, Pennell DJ. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:8.
43. Meloni A, Pepe A, Positano V, Favilli B, Maggio A, Capra M, et al. Influence of myocardial fibrosis and blood oxygenation on heart T2∗values in thalassemia patients. J Magn Reson Imaging. 2009;29:832-7.
44. Kirk P, Smith GC, Roughton M, He T, Pennell DJ. Myocardial T2∗is not affected by ageing, myocardial fibrosis, or impaired left ventricular function. J Magn Reson Imaging. 2010;32:1095-8.
45. Piechnik SK, Ferreira VM, Lewandowski AJ, Ntusi NA, Banerjee R, Holloway C, et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5T using ShMOLLI. J Cardiovasc Magn Reson. 2013;15:13.
46. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, et al. Calibration of myocardial T2 and T1 against iron concentration. J Cardiovasc Magn Reson. 2014;16:62.
47. Carpenter JP, Roughton M, Pennell DJ. Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2∗cardiovascular magnetic resonance in β-thalassemia major. Haematologica. 2013;98:1368-74.